Met Life Investment Management, LLC Clovis Oncology, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

39 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$1.43 - $3.14 $62,618 - $137,497	-43,789 Closed	0 $0
Q4 2021 May 17, 2024	BUY	$2.7 - $4.76 $62,164 - $109,594	23,024 Added 110.88%	43,789 $118,000
Q4 2021 Jun 21, 2023	BUY	$2.7 - $4.76 $118,230 - $208,435	43,789 New	43,789 $118,000
Q4 2021 Mar 22, 2023	BUY	$2.7 - $4.76 $62,164 - $109,594	23,024 Added 110.88%	43,789 $118,000
Q4 2021 Feb 15, 2022	BUY	$2.7 - $4.76 $62,164 - $109,594	23,024 Added 110.88%	43,789 $119,000
Q3 2021 May 17, 2024	SELL	$4.06 - $5.8 $72,320 - $103,315	-17,813 Reduced 46.17%	20,765 $92,000
Q3 2021 Jun 21, 2023	BUY	$4.06 - $5.8 $84,305 - $120,437	20,765 New	20,765 $92,000
Q3 2021 Mar 22, 2023	SELL	$4.06 - $5.8 $72,320 - $103,315	-17,813 Reduced 46.17%	20,765 $92,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $72,320 - $103,315	-17,813 Reduced 46.17%	20,765 $93,000
Q2 2021 May 17, 2024	BUY	$5.02 - $7.05 $129,651 - $182,080	25,827 Added 202.55%	38,578 $223,000
Q2 2021 Jun 21, 2023	BUY	$5.02 - $7.05 $193,661 - $271,974	38,578 New	38,578 $223,000
Q2 2021 Mar 22, 2023	BUY	$5.02 - $7.05 $129,651 - $182,080	25,827 Added 202.55%	38,578 $223,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $129,651 - $182,080	25,827 Added 202.55%	38,578 $224,000
Q1 2021 May 17, 2024	BUY	$4.81 - $10.34 $61,332 - $131,845	12,751 New	12,751 $89,000
Q1 2021 Jun 26, 2023	BUY	$4.81 - $10.34 $61,332 - $131,845	12,751 New	12,751 $89.5 Million
Q1 2021 Mar 22, 2023	SELL	$4.81 - $10.34 $119,672 - $257,259	-24,880 Reduced 66.12%	12,751 $89,000
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $119,672 - $257,259	-24,880 Reduced 66.12%	12,751 $90,000
Q4 2020 May 24, 2024	BUY	$4.13 - $6.41 $15,095 - $23,428	3,655 Added 10.76%	37,631 $180,000
Q4 2020 Jun 22, 2023	BUY	$4.13 - $6.41 $155,416 - $241,214	37,631 New	37,631 $180,000
Q4 2020 Mar 22, 2023	BUY	$4.13 - $6.41 $15,095 - $23,428	3,655 Added 10.76%	37,631 $180,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $15,095 - $23,428	3,655 Added 10.76%	37,631 $181,000
Q3 2020 Jun 26, 2023	BUY	$4.82 - $7.72 $163,764 - $262,294	33,976 New	33,976 $198,000
Q2 2020 May 24, 2024	BUY	$5.69 - $9.69 $193,323 - $329,227	33,976 New	33,976 $229 Million
Q2 2020 Jun 26, 2023	BUY	$5.69 - $9.69 $193,323 - $329,227	33,976 New	33,976 $229,000
Q2 2020 Mar 22, 2023	BUY	$5.69 - $9.69 $68,331 - $116,367	12,009 Added 54.67%	33,976 $229,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $68,331 - $116,367	12,009 Added 54.67%	33,976 $229,000
Q1 2020 Jul 12, 2023	BUY	$3.77 - $11.0 $82,815 - $241,637	21,967 New	21,967 $139,000
Q4 2019 Jul 12, 2023	BUY	$3.0 - $16.43 $65,901 - $360,917	21,967 New	21,967 $229,000
Q3 2019 Jul 12, 2023	BUY	$3.93 - $15.35 $86,330 - $337,193	21,967 New	21,967 $86,000
Q2 2019 Jul 12, 2023	BUY	$12.81 - $25.67 $281,397 - $563,892	21,967 New	21,967 $326,000
Q1 2019 Jul 13, 2023	BUY	$17.66 - $30.28 $387,937 - $665,160	21,967 New	21,967 $545,000
Q4 2018 Jul 13, 2023	BUY	$11.63 - $32.67 $255,476 - $717,661	21,967 New	21,967 $394,000
Q4 2018 Mar 22, 2023	SELL	$11.63 - $32.67 $140,909 - $395,829	-12,116 Reduced 35.55%	21,967 $394,000
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $140,909 - $395,829	-12,116 Reduced 35.55%	21,967 $395,000
Q3 2018 Jul 13, 2023	BUY	$29.37 - $49.48 $645,170 - $1.09 Million	21,967 New	21,967 $645,000
Q3 2018 Mar 22, 2023	BUY	$29.37 - $49.48 $1 Million - $1.69 Million	34,083 New	34,083 $1 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $355,846 - $599,499	12,116 Added 55.16%	34,083 $1 Million
Q2 2018 Aug 15, 2018	BUY	$42.06 - $62.4 $74,193 - $110,073	1,764 Added 8.73%	21,967 $999,000
Q4 2017 Feb 15, 2018	BUY	$57.69 - $84.58 $1.17 Million - $1.71 Million	20,203	20,203 $1.37 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account